退市5年，龙力生物案判决出炉！1618名投资者获赔超2.7亿元

Core Viewpoint - The first-instance judgment regarding the securities false statement liability dispute of Shandong Longli Biological Technology Co., Ltd. has been issued after five years of delisting, with 1,618 investors participating in the lawsuit and claiming a total of 274 million yuan in investment loss [1][2][3]. Group 1: Legal Proceedings and Financial Implications - The Jinan Intermediate People's Court ruled that the 1,618 plaintiffs are entitled to a total investment loss claim of 274 million yuan and legal fees of 809,000 yuan, with five representative plaintiffs also entitled to notification fees of 80,600 yuan [1][3]. - Defendant Cheng Shaobo is jointly liable for the debts owed to the plaintiffs, while other defendants bear joint liability within a certain proportion [1][3]. - Guolian Minsheng Securities is liable for 5% of the plaintiffs' losses, while Lixin Accounting Firm is liable for 30% of the plaintiffs' losses [1][3]. Group 2: Company Background and Historical Context - Longli Biological was listed on the Shenzhen Stock Exchange on July 28, 2011, under the stock code 002604, and was known as the "first stock of biofuels" [2]. - The company was placed under risk warning on January 19, 2018, and was officially delisted on July 1, 2020, transitioning to the National Equities Exchange and Quotations [2]. - The China Securities Regulatory Commission previously identified Longli Biological for significant fraud, leading to penalties including a fine of 600,000 yuan for the company and 1.5 million yuan for Cheng Shaobo [2]. Group 3: Future Considerations and Company Status - Following the judgment, the parties involved may appeal to the Shandong High People's Court, indicating that the final outcome remains uncertain [4]. - Guolian Minsheng Securities stated that the lawsuit will not have a significant adverse impact on the company's current or future profits, as the financial status of the company remains stable and operations are normal [4].